Drugs Approved by the FDA (2008)

The following drugs have been approved this year by the Food and Drug Administration

Endocrinology

Accretropin (somatropin rDNA Original); For the treatment of growth failure in pediatrics; Cangene Corp; Approved January 2008
Welchol (colesevelam hydrochloride); For the improvement of glycemic control in adults with type 2 diabetes mellitus; Daiichi Sankyo; Approved January 2008

Gastroenterology

Tysabri (natalizumab); For the maintenance treatment of moderate to severe Crohn’s disease; Biogen IDEC; Approved January 2008

Immunology/Infectious Diseases

Intelence (etravirine); For the treatment of HIV-1; Tibotec; Approved January 2008
Moxatag (amoxicillin); For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics; MiddleBrooke Pharmaceuticals; Approved January 2008
Tysabri (natalizumab); For the maintenance treatment of moderate to severe Crohn’s disease; Biogen IDEC; Approved January 2008

Oncology

Treanda (bendamustine hydrochloride); For the treatment of chronic lymphocytic leukemia; Cephalon; Approved March 2008

Otolaryngology

Moxatag (amoxicillin); For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics; MiddleBrooke Pharmaceuticals; Approved January 2008

Pediatrics/Neonatology

Accretropin (somatropin rDNA Original); For the treatment of growth failure in pediatrics; Cangene Corp; Approved January 2008
Alvesco (ciclesonide); For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents; Nycomed; Approved January 2008
Moxatag (amoxicillin); For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatrics; MiddleBrooke Pharmaceuticals; Approved January 2008

Pulmonary/Respiratory Diseases

Alvesco (ciclesonide); For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents; Nycomed; Approved January 2008

Source : www.centerwatch.com